Takeda said Friday that it will record a legal provision of JPY 402.5 billion ($2.5 billion) in the financial year ended March 31 to cover damages recently awarded by a US jury in a case related to generic versions of of the constipation treatment Amitiza (lubiprostone).
Matthew Dennis
Geo Focus
Coverage Attributes:
Beta
Informative:
54
%
Data Driven:
40
%
Events:
3
%
Interviews Q&as:
1
%
Themes Covered:
Not enough data
Pitching Insights
Matthew Dennis's articles predominantly revolve around the healthcare and pharmaceutical industry, with a focus on drug development, clinical trials, and regulatory announcements. If you are involved in pharmaceutical research or work for a biotech company engaged in drug development or clinical trials, providing insights into these areas could interest Matthew.
Given that his coverage heavily includes press releases and cites data frequently, he may be interested in receiving pitches related to new findings from clinical trials, FDA approvals/rejections of drugs, or any significant developments within biotech companies supported by concrete data.
It is evident that there is no explicit geographic focus mentioned; however, Matthew covers international news related to the healthcare and pharmaceutical industry without specific regional limitations.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Journalists With Similar Coverage:
Based on similarity of content.
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
